DOTA-1: Single-Fraction MR-guided Stereotactic Ablative Radiotherapy for Localized Prostate Cancer (DOTA-1)
DOminant-TArgeted Stereotactic Ablative Radiotherapy in Localized Prostate Cancer: Single-fraction Phase I/II Pilot Study (DOTA-1)
This single-center, single-arm phase I/II pilot study evaluates the safety and feasibility of single-fraction stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) in men with localized prostate cancer.
Ten participants with very low-, low-, or favorable intermediate-risk prostate adenocarcinoma and an MRI-visible DIL (PI-RADS 4-5) will be enrolled. After hydrogel rectal spacer insertion, patients receive MR-guided SBRT on an MR-Linac in one fraction: 20 Gy to the whole prostate, 26 Gy to the DIL, and 15 Gy to the seminal vesicles. The aim is to deliver a brachytherapy-like ablative dose without an invasive procedure.
The primary outcome is acute genitourinary and rectal toxicity (CTCAE v5.0) within 3 months after treatment. Secondary outcomes include late toxicity, patient-reported quality of life (IPSS, IIEF, FACT-P), biochemical failure-free survival (Phoenix definition), local recurrence-free, progression-free, distant metastasis-free and overall survival, correlation of MR-radiomics with clinical outcomes, and cost-effectiveness. Patients will be followed for 5 years.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Ratchapas Romrattaphan, MD
- 电话号码:+6624197229
- 邮箱:ratchapas.rom@gmail.com
学习地点
-
-
Bangkok
-
Bangkok Noi、Bangkok、泰国、10700
- 招聘中
- Siriraj Hospital
-
接触:
- Ratchapas Romrattaphan, MD
- 电话号码:+6624197229
- 邮箱:ratchapas.rom@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Men ≥ 18 years old
-
Newly diagnosed and histologically confirmed localized prostate adenocarcinoma
-
Very low-, low-, and favorable intermediate-risk via NCCN risk group classification, defined as;
- Gleason grade group 1 or 2
- Clinical stage T1-T2c
- Initial PSA < 20 ng/ml (Patient can have only one of cT2b-cT2c, Gleason grade group 2 and PSA 10-20 ng/ml)
-
Visible dominant-intraprostatic lesion (DIL) on multi-parametric MRI defined by PI-RADS classification
-
ECOG Performance Status 0-2 within 28 days prior to study entry
-
Patients must be able to provide study-specific informed consent prior to study entry.
Exclusion Criteria:
- Direct extraprostatic extension into the adjacent structures
- Extraprostatic metastases or malignant nodes
- Large prostate volume > 60 cm3 by imaging
- Use of Androgen deprivation therapy
- Baseline IPSS > 13
- MRI-contraindicated patient (eg., MRI-incompatible pacemaker, metal implant)
- Patient with hip prosthesis which causes artifact on MR images
- Patient with significant predisposing comorbidity (eg. inflammatory bowel disease)
- Prior radiotherapy to the region of the pelvis that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 2 years (Note that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single-fraction MR-guided SBRT
|
A single fraction of stereotactic body radiotherapy (SBRT) delivered on a 1.5T MR-Linac with daily MRI guidance, using IMRT with a simultaneous integrated boost. Prescribed doses: 26 Gy to the dominant intraprostatic lesion (DIL; PI-RADS 4-5 lesion on multiparametric MRI), 20 Gy to the whole prostate, and 15 Gy to the seminal vesicles. A hydrogel rectal spacer is inserted before CT/MR simulation. Before simulation and treatment, patients follow a bladder protocol (void, then drink 200-300 mL of water) and empty the rectum. No androgen deprivation therapy is given.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Acute toxicity (Genitourinary and Gastrointestinal toxicity)
大体时间:Up to 3 months after SBRT
|
Incidence of acute treatment-related toxicity from the date of treatment by radiotherapy up to 3 months after completion of radiotherapy, assessed using CTCAE version 5.0 |
Up to 3 months after SBRT
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Late toxicity (Genitourinary and Gastrointestinal toxicity)
大体时间:From 3 months to 5 years after SBRT
|
Incidence of late (chronic) treatment-related toxicity from 3 months after completion of radiotherapy up to 5 years after completion of radiotherapy, assessed using CTCAE version 5.0 |
From 3 months to 5 years after SBRT
|
|
International Prostate Symptom Score (I-PSS)
大体时间:Baseline and at each follow-up visit up to 5 years after SBRT
|
Patient-reported urinary symptoms assessed using the I-PSS. The total score ranges from 0 to 35; higher scores indicate worse urinary symptoms. |
Baseline and at each follow-up visit up to 5 years after SBRT
|
|
International Index of Erectile Function (IIEF-5) score
大体时间:Baseline and at each follow-up visit up to 5 years after SBRT
|
Patient-reported erectile function assessed using the IIEF-5 Score. The total score ranges from 5 to 25; higher scores indicate better erectile function. |
Baseline and at each follow-up visit up to 5 years after SBRT
|
|
Functional Assessment of Cancer Therapy - Prostate (FACT-P) score
大体时间:Baseline and at each follow-up visit up to 5 years after SBRT
|
Health-related quality of life assessed using the FACT-P. The total score ranges from 0 to 156; higher scores indicate better quality of life. |
Baseline and at each follow-up visit up to 5 years after SBRT
|
|
Freedom from biochemical failure
大体时间:5 years after SBRT
|
Time from SBRT to biochemical failure, defined by the Phoenix criteria (PSA nadir + 2 ng/mL), estimated by the Kaplan-Meier method. |
5 years after SBRT
|
|
Local recurrence-free survival
大体时间:5 years after SBRT
|
Time from SBRT to recurrence within the prostate, estimated by the Kaplan-Meier method. |
5 years after SBRT
|
|
Overall survival
大体时间:5 years after SBRT
|
Time from SBRT to death from any cause, estimated by the Kaplan-Meier method. |
5 years after SBRT
|
|
Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY)
大体时间:5 years after SBRT
|
Cost and utility data will be used to evaluate cost-effectiveness by calculating the incremental cost-effectiveness ratio (ICER). Uncertainty analyses will be performed using one-way sensitivity analysis, probabilistic sensitivity analysis, and threshold analysis. |
5 years after SBRT
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- Si 703/2568 (IRB4)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data will not be shared outside the study team. The informed consent and ethics approval do not cover data sharing.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.